Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Boston Medical Group vs HumeCare+

Boston Medical Group
Graded #279

Higher grade

vs+3.299999999999997
HumeCare+
Graded #366

Lower grade

The verdict

Boston Medical Group takes it — 61.9/100 to 58.6/100.

Boston Medical Group grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Boston Medical Group is an established medical group running a 12-week compounded GLP-1 weight-loss programme.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueEven
54
54
Dose & formulationEven
52
52
Clinical oversightBoston Medical Group +18
89
71
Labs & monitoringEven
53
53
FulfillmentBoston Medical Group +1
65
64
Contract termsHumeCare+ +6
55
61
Boston Medical Group · left barHumeCare+ · right bar

The numbers

MetricBoston Medical GroupHumeCare+
WeighScore61.9/10058.6/100
GradeCC
Scorecard rank#279#366
Semaglutide$199/mo (starting strength, rising with dose, compounded)$199/mo (starting dose, compounded)
TirzepatideNot disclosedNot disclosed
Coverage7 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Boston Medical Group

Graded #279 · C

Strengths

  • An established medical group with a defined 12-week programme rather than an open-ended subscription
  • The price range and the 12-week total are both published, once you reach the costs page
  • Semaglutide is prescribed and dispensed under a compounded pathway with clinician oversight

Where it loses points

  • The published rate is a range by dose strength, $199 to $299, so the figure quoted is the floor rather than what a titrated patient pays
  • The 12-week programme totals $699 including a telemedicine platform fee that is never itemised — about $233/mo all-in, not $199
  • The weight-loss landing page carries no price at all; the numbers are two pages deeper, in the FAQ and the costs page
  • Semaglutide and tirzepatide are not priced separately — one range covers the whole programme
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products
HumeCare+

Graded #366 · C

Strengths

  • Pairs compounded semaglutide with continuous body-composition tracking (lose fat, preserve muscle)
  • Includes a Hume Pod body-composition device at no extra cost
  • From $199/mo, billed monthly, cancel anytime
  • Backed by Hume Health, an established body-composition scale brand
  • Clinician-prescribed and monitored with weekly tracking

Where it loses points

  • Final medication pricing is gated behind an intake quiz
  • Only semaglutide is shown on the marketing site (tirzepatide not confirmed)
  • Prescribing medical group and pharmacy partner not named
  • States of operation not published
  • Not LegitScript-certified (no certification displayed)

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard